CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review,  September 2016

 

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

A threshold of systemic MAGE-A gene expression predicting survival in resected non-small cell lung cancer. Mecklenburg I1, Sienel W2, Schmid S3, Passlick B4, Kufer P5. Clin Cancer Res. 2016 Aug 19. pii: clincanres.0557.2016. [Epub ahead of print]

Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. Huynh TG1, Morales-Oyarvide V2, Campo MJ3, et al. J Thorac Oncol. 2016 Aug 24. pii: S1556-0864(16)30900-5. doi: 10.1016/j.jtho.2016.08.134. [Epub ahead of print]

Human Leukocyte Antigen G Polymorphism and Expression Are Associated with an Increased Risk of Non-Small-Cell Lung Cancer and Advanced Disease Stage. Ben Amor A1, Beauchemin K2, Faucher MC2, Hamzaoui A1,3, Hamzaoui K1,3, Roger M2,4. PLoS One. 2016 Aug 12;11(8):e0161210. doi: 10.1371/journal.pone.0161210. eCollection 2016.

Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors. Lindsay D1, Garvey CM2, Mumenthaler SM2, Foo J1. PLoS Comput Biol. 2016 Aug 25;12(8):e1005077. doi: 10.1371/journal.pcbi.1005077. eCollection 2016.

A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. Gaule P1, Smithy JW1, Toki M1, et al. JAMA Oncol. 2016 Aug 18. doi: 10.1001/jamaoncol.2016.3015. [Epub ahead of print]

Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates. Tournier N1, Goutal S1, Auvity S1, et al. J Nucl Med. 2016 Aug 4. pii: jnumed.116.178665. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

Dermatological adverse events with taxane chemotherapy. Sibaud V1, Lebœuf NR2, Roche H3, et al. Eur J Dermatol. 2016 Aug 22. [Epub ahead of print]

Weekly vinorelbine and paclitaxel in older patients with advanced non-small cell lung cancer: A phase II Fred and Pamela Buffet Cancer Center Clinical Trials Network study. Huerter MM1, Meza JL2, Copur MS3, et al. J Geriatr Oncol. 2016 Aug 1. pii: S1879-4068(16)30095-9. doi: 10.1016/j.jgo.2016.07.006. [Epub ahead of print]

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. Papadimitrakopoulou V1, Lee JJ2, Wistuba II2, et al. J Clin Oncol. 2016 Aug 1. pii: JCO660084. [Epub ahead of print]

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N1, Economopoulou P1, Christofyllakis C1, et al. Clin Transl Oncol. 2016 Aug 4. [Epub ahead of print]

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Cheng Y1, Murakami H1, Yang PC1, et al. J Clin Oncol. 2016 Aug 9. pii: JCO669218. [Epub ahead of print]

Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Song Z1,2, Su H3, Zhang Y1,2. Cancer Med. 2016 Aug 20. doi: 10.1002/cam4.809. [Epub ahead of print]

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Joerger M1, von Pawel J2, Kraff S3, et al. Ann Oncol. 2016 Aug 8. pii: mdw290. [Epub ahead of print]

Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. Huang M1, Lou Y2, Pellissier J1, Burke T1, Liu FX1, Xu R1, Velcheti V3. J Med Econ. 2016 Aug 29:1-28. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – IMMUNOTHERAPY

The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. Tanvetyanon T1, Creelan BC1, Antonia SJ1. Expert Rev Anticancer Ther. 2016 Aug 22:1-8. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use of Angiotensin-converting Enzyme Inhibitors in Patients Receiving Lung Stereotactic Body Radiation Therapy. Alite F1, Balasubramanian N, Adams W, Surucu M, Mescioglu I, Harkenrider MM. Am J Clin Oncol. 2016 Aug 24. [Epub ahead of print]

Stereotactic Ablative Radiotherapy and immunotherapy combinations: turning the future into systemic therapy? Walshaw RC1, Honeychurch J1, Illidge TM1. Br J Radiol. 2016 Aug 24:20160472. [Epub ahead of print]

Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. Bi N1, Shedden K2, Zheng X3, Kong FM4. Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1378-90. doi: 10.1016/j.ijrobp.2016.04.016.

Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation? de Dios NR1,2,3, Sanz X4,5,6, Foro P4,5,6, Membrive I4,5, Reig A4,5, Ortiz A4,5, Jiménez R4,5, Algara M4,5,6. Clin Transl Oncol. 2016 Aug 23. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Lobe-specific lymph node dissection as a standard procedure in surgery for non-small-cell lung cancer: A propensity score matching study. Adachi H1, Sakamaki K2, Nishii T3, et al. J Thorac Oncol. 2016 Aug 20. pii: S1556-0864(16)30847-4. doi: 10.1016/j.jtho.2016.08.127. [Epub ahead of print]

Anatomical segmentectomy and wedge resections are associated with comparable outcomes for small cT1N0 non-small cell lung cancer. Altorki NK1, Kamel MK2, Narula N3, et al. J Thorac Oncol. 2016 Aug 2. pii: S1556-0864(16)30695-5. doi: 10.1016/j.jtho.2016.06.031. [Epub ahead of print]

Re-Assessment of Intentional Extended Segmentectomy for Clinical T1aN0 Non-Small Cell Lung Cancer. Nishio W1, Yoshimura M2, Maniwa Y3, Kitamura Y2, Tane K2, Takenaka D4, Adachi S4. Ann Thorac Surg. 2016 Aug 12. pii: S0003-4975(16)30566-5. doi: 10.1016/j.athoracsur.2016.05.071. [Epub ahead of print]

The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. Spicer JD1, Shewale JB2, Antonoff MB2, et al. Ann Thorac Surg. 2016 Aug 12. pii: S0003-4975(16)30567-7. doi: 10.1016/j.athoracsur.2016.05.072. [Epub ahead of print]

“Even if I Don’t Remember, I Feel Better”. A Qualitative Study of Patients with Early-Stage Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy or Surgery. Golden SE1, Thomas CR Jr2, Deffebach ME3,4, Sukumar MS5, Schipper PH5, Tieu BH5, Kee AY6,  Ann Am Thorac Soc. 2016 Aug;13(8):1361-9. doi: 10.1513/AnnalsATS.201602-130OC.

 

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102. Kubo T1, Fujiwara K2, Hotta K3,4, et al. . Cancer Chemother Pharmacol. 2016 Aug 20. [Epub ahead of print]

Karnofsky Performance Score, Radiation Dose and Nodal Status Predict Survival of Elderly Patients Irradiated for Limited-disease Small-cell Lung Cancer. Käsmann L1, Janssen S2, Rades D3. Anticancer Res. 2016 Aug;36(8):4177-80.

Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer. Toyokawa G1, Takada K2, Haratake N3, Takamori S3, Akamine T3, Katsura M3, Fujishita T3, Shoji F3, Okamoto T3, Oda Y4, Maehara Y3. Anticancer Res. 2016 Aug;36(8):4329-36.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer. Halvorsen TO1,2, Sundstrøm S2, Fløtten Ø3, et al. Acta Oncol. 2016 Aug 23:1-9. [Epub ahead of print]

Barasertib,(AZD1152)a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Helfrich BA1, Kim J1, Gao D2, Chan DC1, Zhang Z1, Tan AC1, Bunn PA3. Mol Cancer Ther. 2016 Aug 5. pii: molcanther.0298.2016. [Epub ahead of print]

Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. Oh IJ1, Kim KS1, Park CK1, et al. BMC Cancer. 2016 Aug 26;16:690. doi: 10.1186/s12885-016-2741-z.

COMPLEMENTARY & ALTERNATIVE THERAPY

A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer. Tsai MY1,2,3, Hung YC4,5, Chen YH6, Chen YH7, Huang YC8, Kao CW4, Su YL6, Chiu HH5, Rau KM9. BMC Complement Altern Med. 2016 Aug 26;16(1):322. doi: 10.1186/s12906-016-1312-9.

Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. Lou JS1,2, Yan L1, Bi CW1,2, Chan GK1, Wu QY1, Liu YL1, Huang Y1, Yao P1, Du CY3, Dong TT1, Tsim KW1. Sci Rep. 2016 Aug 25;6:31926. doi: 10.1038/srep31926.

MISCELLANEOUS WORKS

Identifying Subsequent Therapies in Patients with Advanced Non-Small-Cell Lung Cancer and Factors Associated with Overall-Survival. Afanasjeva J1,2, Hui RL3, Spence MM3, et al. Pharmacotherapy. 2016 Aug 13. doi: 10.1002/phar.1826. [Epub ahead of print]

The Association between Ambient Fine Particulate Air Pollution and Lung Cancer Incidence: Results from the AHSMOG-2 Study. Gharibvand L1, Shavlik D2, Ghamsary M3, Beeson WL1,2, Soret S3, Knutsen R1,2, Knutsen SF1,2. Environ Health Perspect. 2016 Aug 12. [Epub ahead of print]

Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes – A Meta-analysis. Chen LS1, Baker T2, Hung RJ3, et al. EBioMedicine. 2016 Aug 10. pii: S2352-3964(16)30361-9. doi: 10.1016/j.ebiom.2016.08.012. [Epub ahead of print]

Creating Virtual Integration and Improved Oncology Care Quality Through a Co-Management Services Agreement. Hartung NL1, Henschel RM2, Smith KB1, Gesme DH Jr1. J Oncol Pract. 2016 Aug 9. pii: JOPR010645. [Epub ahead of print]

Damaging Effects of Cannabis Use on the Lungs. Yayan J1, Rasche K2. Adv Exp Med Biol. 2016 Aug 30. [Epub ahead of print]

Treatment patterns and cost-effectiveness of first line treatment of advanced nonsquamous non-small cell lung cancer in Medicare patients. Gilden DM1, Kubisiak JM1, Pohl GM2, Ball DE2, Gilden DE1, John WJ2, Wetmore S2, Winfree KB2. J Med Econ. 2016 Aug 30:1-23. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Preparing Cancer Patients and Family Caregivers for Lung Surgery: Development of a Multimedia Self-Management Intervention. Sun V1, Kim JY2, Raz DJ2, et al. J Cancer Educ. 2016 Aug 20. [Epub ahead of print]

The prevalence and nature of supportive care needs in lung cancer patients. Giuliani ME1, Milne RA1, Puts M2, et al. Curr Oncol. 2016 Aug;23(4):258-65. doi: 10.3747/co.23.3012. Epub 2016 Aug 12.

The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer. Duggan KT1, Duffus SH1, D’Agostino RB Jr1, Petty WJ1, Streer NP1, Stephenson RC1. J Palliat Med. 2016 Aug 25. [Epub ahead of print]

Sharing bad news of a lung cancer diagnosis: understanding through communication privacy management theory. Ngwenya N1, Farquhar M2, Ewing G1. Psychooncology. 2016 Aug;25(8):913-8. doi: 10.1002/pon.4024. Epub 2015 Nov 25.

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Volovat C1, Bondarenko I2, Gladkov O3, et al. Support Care Cancer. 2016 Aug 8. [Epub ahead of print]

Patient-reported symptom interference as a measure of postsurgery functional recovery in lung cancer. Shi Q1, Wang XS2, Vaporciyan AA3, Rice DC3, Popat KU4, Cleeland CS1. J Pain Symptom Manage. 2016 Aug 10. pii: S0885-3924(16)30223-8. doi: 10.1016/j.jpainsymman.2016.07.005. [Epub ahead of print]

Predictors of responses to corticosteroids for anorexia in advanced cancer patients: a multicenter prospective observational study. Matsuo N1, Morita T2, Matsuda Y3, et al. Support Care Cancer. 2016 Aug 18. [Epub ahead of print]

How Does Caregiver Well-Being Relate to Perceived Quality of Care in Patients With Cancer? Exploring Associations and Pathways. Litzelman K1, Kent EE2, Mollica M2, Rowland JH2. J Clin Oncol. 2016 Aug 29. pii: JCO673434. [Epub ahead of print]

SCREENING, DIAGNOSIS AND STAGING

Patient Perspectives on Low-Dose Computed Tomography for Lung Cancer Screening, New Mexico, 2014. Mishra SI1, Sussman AL2, Murrietta AM3, et al. Prev Chronic Dis. 2016 Aug 18;13:E108. doi: 10.5888/pcd13.160093.

Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. Schabath MB1, Massion PP2, Thompson ZJ3, Eschrich SA4, Balagurunathan Y5, Goldof D6, Aberle DR7, Gillies RJ5. PLoS One. 2016 Aug 10;11(8):e0159880. doi: 10.1371/journal.pone.0159880. eCollection 2016.

Sociocultural Barriers to Lung Cancer Screening Among Korean Immigrant Men. Sin MK1, Ha A2, Taylor V3. J Community Health. 2016 Aug;41(4):790-7. doi: 10.1007/s10900-016-0154-1.

FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. Arens AI1, Postema JW2, Schreurs WM3, Lafeber A4, Hendrickx BW5, Oyen WJ2, Vogel WV4. PLoS One. 2016 Aug 24;11(8):e0160539. doi: 10.1371/journal.pone.0160539. eCollection 2016.

A Comparison of Lung Nodule Segmentation Algorithms: Methods and Results from a Multi-institutional Study. Kalpathy-Cramer J1, Zhao B2, Goldgof D3, Gu Y4, Wang X5, Yang H2, Tan Y2, Gillies R4, Napel S6. J Digit Imaging. 2016 Aug;29(4):476-87. doi: 10.1007/s10278-016-9859-z.

Rationale for a Minimum Number of Lymph Nodes Removed with Non-Small Cell Lung Cancer Resection: Correlating the Number of Nodes Removed with Survival in 98,970 Patients. Samayoa AX1, Pezzi TA2, Pezzi CM3, et al. Ann Surg Oncol. 2016 Aug 16. [Epub ahead of print]

Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement. Wu J1, Lin Y1, He X1, Yang H2, He P1, Fu X1, Li G1, Gu X3. BMC Cancer. 2016 Aug 4;16:599. doi: 10.1186/s12885-016-2582-9.

Effects of Implementation of Lung Cancer Screening at One Veterans Affairs Medical Center. Okereke IC1, Bates MF2, Jankowich MD3, Rounds SI3, Kimble BA3, Baptiste JV3, Ng TT2, Nici LL3. Chest. 2016 Aug 24. pii: S0012-3692(16)57740-X. doi: 10.1016/j.chest.2016.08.1431. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)